INTIVA BioPharma Inc. is developing, licensing and commercializing
cannabinoid based medications for specific medical conditions and disorders.
Our drug development activities are undertaken in accordance with Food and Drug Administration [ FDA ]
or comparable development pathways in other countries.
Our intent is that any medications we develop will be physician prescription based.
The Company is researching and developing drug and cannabinoid molecules
for various medical conditions and diseases. ArcView Market Research estimates that
America's pharmaceutical cannabis sector could reach over $23 billion by 2020.
Because of the federal illegality of cannabis in the United States,
INTIVA is focusing its initial drug development using synthetic cannabinoids,
some of which are approved by the FDA for various medical conditions.
Synthetic cannabinoids generally simplify research development in the U.S.
However, INTIVA also intends to proceed with trials using plant-derived cannabinoids.
Because of the difficulty in proceeding with those trials in the United States,
the INTIVA will likely proceed with those trials in jurisdictions where the research is legal, such as Israel.
Recent INVTIVA BIOPHARMA INC. SEC FILINGS
Shares O/S Approx 44 Million
Recent Company NEWS
Intiva BioPharma Submits a Request to the FDA for a Pre-Investigational New Drug Meeting
for a Pharmaceutical Product for Use in the Acute Treatment During and Immediately Following Exposure to Nerve Agents
NEW Intiva Biopharma Investor Relations Announced